Bavarian Nordic Awarded Multi-Million Dollar Contract for Smallpox and Monkeypox Vaccines

Company to Manufacture Freeze-Dried Version of JYNNEOS Vaccine

Contract Valued at USD 120 Million

Bavarian Nordic has received a USD 120 million contract from the Biomedical Advanced Research and Development Authority (BARDA) to manufacture and supply its freeze-dried JYNNEOS vaccine for smallpox and monkeypox. The freeze-dried vaccine will replace the current stockpile of liquid-frozen JYNNEOS vaccine with a longer shelf life.

The contract includes an initial order valued at USD 539 million for the delivery of freeze-dried JYNNEOS doses. This order is intended to replenish the U.S. Strategic National Stockpile with a more stable and longer-lasting vaccine.

"We are pleased to continue our collaboration with BARDA to support the U.S. government's preparedness efforts against smallpox and monkeypox," said Paul Chaplin, President and Chief Executive Officer of Bavarian Nordic. "The freeze-dried JYNNEOS vaccine is a significant improvement over the liquid-frozen vaccine, providing enhanced stability and ease of use."